127 related articles for article (PubMed ID: 1333789)
1. Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2.
Miles DW; Aderka D; Engelmann H; Wallach D; Balkwill FR
Br J Cancer; 1992 Dec; 66(6):1195-9. PubMed ID: 1333789
[TBL] [Abstract][Full Text] [Related]
2. Relationship between soluble tumor necrosis factor (TNF) receptors and TNF alpha during immunotherapy with interleukin-2 and/or interferon alpha.
Landmann R; Keilholz U; Scheibenbogen C; Brockhaus M; Gallati H; Denz H; Bargetzi M; Ludwig C
Cancer Immunol Immunother; 1994 Feb; 38(2):113-8. PubMed ID: 8306366
[TBL] [Abstract][Full Text] [Related]
3. LPS-induced sTNF-receptor release in vivo in a murine model. Investigation of the role of tumor necrosis factor, IL-1, leukemia inhibiting factor, and IFN-gamma.
Bemelmans MH; Gouma DJ; Buurman WA
J Immunol; 1993 Nov; 151(10):5554-62. PubMed ID: 8228246
[TBL] [Abstract][Full Text] [Related]
4. Association between biosynthesis of nitric oxide and changes in immunological and vascular parameters in patients treated with interleukin-2.
Miles D; Thomsen L; Balkwill F; Thavasu P; Moncada S
Eur J Clin Invest; 1994 Apr; 24(4):287-90. PubMed ID: 8050458
[TBL] [Abstract][Full Text] [Related]
5. [Soluble TNF and IL-2 receptors in patients with breast carcinoma].
Tesarová P; Kvasnicka J; Umlaufová A; Homolková J; Jirsa M; Tesar V
Cas Lek Cesk; 1998 May; 137(11):341-5. PubMed ID: 9727208
[TBL] [Abstract][Full Text] [Related]
6. Soluble TNF and IL-2 receptors in patients with breast cancer.
Tesarová P; Kvasnicka J; Umlaufová A; Homolková H; Jirsa M; Tesar V
Med Sci Monit; 2000; 6(4):661-7. PubMed ID: 11208388
[TBL] [Abstract][Full Text] [Related]
7. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma.
Du Bois JS; Trehu EG; Mier JW; Shapiro L; Epstein M; Klempner M; Dinarello C; Kappler K; Ronayne L; Rand W; Atkins MB
J Clin Oncol; 1997 Mar; 15(3):1052-62. PubMed ID: 9060545
[TBL] [Abstract][Full Text] [Related]
8. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy.
Barrera P; Boerbooms AM; Janssen EM; Sauerwein RW; Gallati H; Mulder J; de Boo T; Demacker PN; van de Putte LB; van der Meer JW
Arthritis Rheum; 1993 Aug; 36(8):1070-9. PubMed ID: 8393676
[TBL] [Abstract][Full Text] [Related]
9. Soluble tumour necrosis factor receptors, tumour necrosis factor and interleukin-6 in serum in granulocytopenic patients with fever.
Steinshamn S; Brekke OL; Waage A
Br J Haematol; 1995 Apr; 89(4):719-24. PubMed ID: 7772508
[TBL] [Abstract][Full Text] [Related]
10. Analysis of tumor necrosis factor-alpha, interleukin-6, interleukin-1beta, soluble tumor necrosis factor receptors I and II, interleukin-6 soluble receptor, interleukin-1 soluble receptor type II, interleukin-1 receptor antagonist, and protein in the synovial fluid of patients with temporomandibular joint disorders.
Kaneyama K; Segami N; Sun W; Sato J; Fujimura K
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Mar; 99(3):276-84. PubMed ID: 15716832
[TBL] [Abstract][Full Text] [Related]
11. Soluble tumor necrosis factor receptor expression in patients with metastatic renal cell carcinoma treated with interleukin-2-based immunotherapy.
Belldegrun A; Pierce W; Sayah D; deKernion J; Wallach D; Aderka D; Figlin RA
J Immunother Emphasis Tumor Immunol; 1993 Apr; 13(3):175-80. PubMed ID: 8385988
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-10 and soluble tumor necrosis factor receptors in cerebrospinal fluid of children with bacterial meningitis.
Kornelisse RF; Savelkoul HF; Mulder PH; Suur MH; van der Straaten PJ; van der Heijden AJ; Sukhai RN; Hählen K; Neijens HJ; de Groot R
J Infect Dis; 1996 Jun; 173(6):1498-502. PubMed ID: 8648229
[TBL] [Abstract][Full Text] [Related]
13. High blood soluble receptor p80 for tumour necrosis factor-alpha is associated with erythropoietin resistance in haemodialysis patients.
Kato A; Odamaki M; Takita T; Furuhashi M; Maruyama Y; Hishida A
Nephrol Dial Transplant; 2001 Sep; 16(9):1838-44. PubMed ID: 11522867
[TBL] [Abstract][Full Text] [Related]
14. Treatment of malignant melanoma and renal cell carcinoma with recombinant human interleukin-2: analysis of cytokine levels in sera and culture supernatants.
McIntyre CA; Chapman K; Reeder S; Dorreen MS; Bruce L; Rodgers S; Hayat K; Schreenivasan T; Sheridan E; Hancock BW
Eur J Cancer; 1992; 28(1):58-63. PubMed ID: 1567693
[TBL] [Abstract][Full Text] [Related]
15. Systemic release of soluble TNF receptors after high-dose TNF in isolated limb perfusion.
Gérain J; Liénard D; Pampallona S; Baumgartner M; Rüegg C; Buurman WA; Eggermont A; Lejeune F
Cytokine; 1997 Dec; 9(12):1034-42. PubMed ID: 9417816
[TBL] [Abstract][Full Text] [Related]
16. Prevention and treatment of experimental crescentic glomerulonephritis by blocking tumour necrosis factor-alpha.
Karkar AM; Smith J; Pusey CD
Nephrol Dial Transplant; 2001 Mar; 16(3):518-24. PubMed ID: 11239025
[TBL] [Abstract][Full Text] [Related]
17. Expression and cleavage of tumor necrosis factor-alpha and tumor necrosis factor receptors by human monocytic cell lines upon direct contact with stimulated T cells.
Vey E; Burger D; Dayer JM
Eur J Immunol; 1996 Oct; 26(10):2404-9. PubMed ID: 8898953
[TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of proinflammatory cytokine inhibitors (sTNFR I, sTNFR II, IL-1 ra), anti-inflammatory cytokines (IL-10, IL-13) and activation of neutrophils after burn-induced inflammation.
Sikora JP; Chlebna-Sokół D; Andrzejewska E; Chrul S; Polakowska E; Wysocka A; Sikora A
Scand J Immunol; 2008 Aug; 68(2):145-52. PubMed ID: 18702744
[TBL] [Abstract][Full Text] [Related]
19. The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis.
Robak T; Gladalska A; Stepień H
Eur Cytokine Netw; 1998 Jun; 9(2):145-54. PubMed ID: 9681390
[TBL] [Abstract][Full Text] [Related]
20. In vivo tumor necrosis factor-alpha as indicator of biologic and clinical response to low-dose SC recombinant interleukin 2.
Meffert M; Schomburg A; Hänninen EL; Menzel T; Vocke S; Dallmann I; Grosse J; Duensing S; Buer J; Kirchner H
Anticancer Res; 1995; 15(1):127-32. PubMed ID: 7733621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
